Phase I Trial of Bevacizumab, Metronomic Doxorubicin and Radiation Therapy for Resectable Soft Tissue Sarcoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 11 Dec 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 25 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 22 Feb 2017 Status changed from recruiting to active, no longer recruiting.